Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

Inclusion Criteria: * Children 0-18 years of age * Patients will be PN-dependent and expected to continue PN for at least 30 days * Patients considered eligible for study participation must have PN-associated liver diseases . Other causes of liver disease (i.e., biliary atresia, galactosemia, alpha-1 antitrypsin deficiency) will be excluded. A liver biopsy is not necessary for treatment * Direct bilirubin \> 2.0 mg/dl * Signed patient informed consent * Signed patient assent where applicable. Exclusion Criteria: * Pregnancy * Other causes of chronic liver disease (cystic fibrosis, biliary atresia, alpha-1 antitrypsin deficiency) * Signs of advanced liver disease including cirrhosis on biopsy, varices, ascites * The patient is allergic to eggs/shellfish * The patient has a severe hemorrhagic disorder * The patient is enrolled in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team) * The parent or guardian or child unwilling to provide consent or assent.